Citizens & Northern Corp increased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 15,726 shares of the biopharmaceutical company’s stock after buying an additional 464 shares during the period. Citizens & Northern Corp’s holdings in Gilead Sciences were worth $1,126,000 at the end of the most recent reporting period.
A number of other hedge funds also recently modified their holdings of GILD. West Oak Capital LLC boosted its stake in shares of Gilead Sciences by 0.7% in the third quarter. West Oak Capital LLC now owns 4,449 shares of the biopharmaceutical company’s stock worth $352,000 after buying an additional 32 shares during the last quarter. Kempner Capital Management Inc. bought a new stake in shares of Gilead Sciences during the third quarter worth approximately $855,000. Eqis Capital Management Inc. boosted its stake in shares of Gilead Sciences by 1.3% in the third quarter. Eqis Capital Management Inc. now owns 71,366 shares of the biopharmaceutical company’s stock worth $5,646,000 after buying an additional 897 shares during the last quarter. BNP Paribas Arbitrage SA boosted its stake in shares of Gilead Sciences by 28.1% in the third quarter. BNP Paribas Arbitrage SA now owns 2,779,750 shares of the biopharmaceutical company’s stock worth $219,934,000 after buying an additional 609,110 shares during the last quarter. Finally, Curbstone Financial Management Corp boosted its stake in shares of Gilead Sciences by 5.3% in the third quarter. Curbstone Financial Management Corp now owns 26,800 shares of the biopharmaceutical company’s stock worth $2,120,000 after buying an additional 1,340 shares during the last quarter. Institutional investors and hedge funds own 74.19% of the company’s stock.
Gilead Sciences, Inc. (NASDAQ:GILD) opened at 68.71 on Tuesday. Gilead Sciences, Inc. has a 52 week low of $65.38 and a 52 week high of $103.10. The company’s 50-day moving average price is $69.69 and its 200-day moving average price is $73.79. The company has a market capitalization of $89.81 billion, a price-to-earnings ratio of 6.91 and a beta of 1.11.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 7th. The biopharmaceutical company reported $2.70 EPS for the quarter, topping the Zacks’ consensus estimate of $2.61 by $0.09. Gilead Sciences had a return on equity of 92.36% and a net margin of 44.43%. The company earned $7.30 billion during the quarter, compared to analysts’ expectations of $7.16 billion. During the same quarter in the previous year, the firm posted $3.32 EPS. The firm’s revenue was down 13.9% compared to the same quarter last year. Equities analysts forecast that Gilead Sciences, Inc. will post $8.24 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 30th. Shareholders of record on Thursday, March 16th will be paid a dividend of $0.52 per share. The ex-dividend date is Tuesday, March 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 3.03%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.47. Gilead Sciences’s dividend payout ratio (DPR) is presently 18.91%.
Your IP Address:
GILD has been the subject of a number of analyst reports. Stifel Nicolaus restated a “buy” rating and issued a $100.00 price target on shares of Gilead Sciences in a research report on Wednesday, November 30th. Jefferies Group LLC restated a “buy” rating and issued a $91.00 price target on shares of Gilead Sciences in a research report on Thursday, December 1st. Piper Jaffray Companies restated an “overweight” rating and issued a $102.00 price target on shares of Gilead Sciences in a research report on Sunday, December 4th. Credit Suisse Group AG set a $93.00 price target on Gilead Sciences and gave the stock a “buy” rating in a research report on Tuesday, December 20th. Finally, Robert W. Baird restated an “outperform” rating and issued a $100.00 price target on shares of Gilead Sciences in a research report on Wednesday, December 21st. One research analyst has rated the stock with a sell rating, ten have issued a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Gilead Sciences presently has an average rating of “Buy” and an average target price of $83.19.
In other Gilead Sciences news, insider John C. Martin sold 73,337 shares of Gilead Sciences stock in a transaction dated Tuesday, January 3rd. The stock was sold at an average price of $73.59, for a total transaction of $5,396,869.83. Following the completion of the transaction, the insider now owns 3,204,433 shares in the company, valued at approximately $235,814,224.47. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.40% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.